iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 805 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC June 24, 2026 Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally... July 8, 2021 Surgery for Recurrent Ovarian Cancer Does Not Improve Survival December 10, 2019 Snowboarder Kimmy Fasani Diagnosed with Breast Cancer Nine Months After Son’s... December 11, 2021 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΩΟΘΗΚΩΝ ‘Scandinavian quality and Singaporean efficiency’: what the autumn statement means for... Oncogenic Drivers Associated with Late Recurrence in Postmenopausal Women with ER-positive/HER2-negative... Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs...
